Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine if the medication Carbamazepine, can be used as a
therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH) Novartis University of Pittsburgh
Treatments:
Alpha 1-Antitrypsin Carbamazepine Protein C Inhibitor